<p>儘管大麻行業在美國幾乎已經合法化，但並非唯一一種試圖突破監管障礙的替代醫學形式。像溴酰胺、麥角酸和氯胺酮這樣的化合物都被稱為致幻劑，然而它們可能具有剛開始被探索的醫療應用。</p>
<p>因此，一些新近上市的公司已經開始嘗試利用這些化合物的治療潛力。當這些公司首次上市時，圍繞其項目的興奮迅速推高了它們的交易價值，隨後緊隨其後的拋售使大多數公司陷入了顯著的低谷。</p>
<p>然而，有幾隻強勁的致幻股票可以在低谷時購買，以獲取潛在的豐厚回報。這是因為幾項研究表明，當以正確劑量給藥時，LSD、溴酰胺和氯胺酮都非常有效地治療抑鬱症。因此，這些公司可能只是時間問題，它們將迎來他們的輝煌時刻。</p>
<h2>ATAI 生命科學（ATAI）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p>作為對替代療法的更廣泛投資，<strong>ATAI 生命科學</strong>（納斯達克：<strong>ATAI</strong>）目前正在研究基於氯胺酮、伊波甲醚和 N,N-二甲基色胺（DMT）等致幻物質的多種藥物。儘管這些化合物可能以娛樂用途而聞名，但已經有幾項同行評議的研究開始探索它們治療心理健康障礙的潛力。</p>
<p>在 ATAI 的情況下，該公司有幾種源自溴酰胺、氯胺酮和 DMT 的藥物正在研發中，其中最有前途的是 COMP360，作為與另一家制藥公司合作的一部分，已進入第三階段臨牀試驗。這種廣泛的治療方法確實給 ATAI 的運營帶來了財務壓力，但提高了突破和潛在的美國食品藥品監督管理局（FDA）批准的可能性。</p>
<p>因此，ATAI 是在低谷時購買的最佳致幻股票之一，因為它目前以其首次公開發行價格的 93% 折扣交易。任何關於其藥物的好消息都可能迅速提振其價值。</p>
<h2>Compass Pathways（CMPS）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p>我之前提到 ATAI 正在與另一家公司開發一種名為 COMP360 的藥物。那家公司就是 <strong>Compass Pathways</strong>（納斯達克：<strong>CMPS</strong>），因此名稱中有 COMP。這種藥物目前是 CMPS 唯一正在開發的項目，這意味着該公司代表了與 ATAI 非常不同類型的製藥投資。</p>
<p>因此，投資於 CMPS 意味着致力於治療中的溴酰胺一側。通過這種方法，投資者知道直接的催化劑取決於 COMP360 的 FDA 批准。因此，讓我們談談 COMP360 背後的研究。目前，CMPS 在其網站上提供了其第 IIb 階段數據表，以供參考其藥物的功效。第 IIb 階段試驗專注於對傳統抗抑鬱化合物抵抗的患者，這意味着選擇性 5-羥色胺再攝取抑制劑等藥物無效。</p>
<p>在研究的總參與者中，有 20% 報告稱在研究第 12 周時持續改善和治療效果。考慮到這些患者已經對治療非常抵抗，這是相當令人印象深刻的。因此，像 CMPS 這樣的致幻股票可能值得投資。</p>
<h2>Cybin（CYBN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p>正如公司名稱所示，<strong>Cybin</strong>（紐交所市場：<strong>CYBN</strong>）專注於開發三種基於溴酰胺的療法，CYB003、CYB004 和 SPL028，同時還在對其他致幻化合物進行臨牀前測試。目前，該股票交易價格僅為 26 美分，處於便士股票領域，這可能會讓一些投資者感到擔憂，但重要的是要記住，該公司的交易歷史相當新，其產品仍在爭取 FDA 批准。</p>
<p>此外，其溴酰胺治療，特別是重氘化溴酰胺計劃已獲得 FDA 授予治療突破性地位，用於治療重性抑鬱症，其第 II 期試驗取得成功。該計劃還經過測試，用於治療酒精濫用障礙，也可能成為該類別的突破性療法。</p>
<p>對於 Cybin，投資者可能希望等到公司能夠產生收入。因為它目前處於增長、研發階段，該公司過去四個季度僅報告了虧損。</p>
<p>_在發佈日期，Viktor Zarev 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，受到 InvestorPlace.com 發佈指南的約束。</p>
<p>_在發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸。</p>
<p>Viktor Zarev 是一位科學家、研究員和作家，專門通過對準確性和理解的執着來解釋技術股票的複雜世界。</p>

CMPS

CYBN

ATAI

<p>最近，受到影響，一些新上市的致幻藥產業公司的交易價值有所下跌。然而，在這種下跌中，有幾隻強勁的致幻藥股票值得考慮購買，包括 ATAI 生命科學（ATAI）、Compass Pathways（CMPS）和 Cybin（CYBN）。這些公司正在進行有關致幻物質潛在醫療應用的研究與開發。ATAI 正在研究基於致幻物質的多種藥物，而 CMPS 專注於賽洛西賓療法的開發。CYBN 專注於開發賽洛西賓療法，並已獲得 FDA 的突破性治療地位</p>

<p>While the cannabis industry has all but become legitimate in the United States, it’s not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.</p>
<div class="lb-trans"><p>儘管大麻行業在美國幾乎已經合法化，但並非唯一一種試圖突破監管障礙的替代醫學形式。像溴酰胺、麥角酸和氯胺酮這樣的化合物都被稱為致幻劑，然而它們可能具有剛開始被探索的醫療應用。</p>
</div><p>As such, several newly minted public companies have begun experimenting with ways to harness the therapeutic potential of these compounds. When these companies first went public, the excitement around their projects quickly spiked their trading value followed by a rapid selloff which put most of them in a significant dip.</p>
<div class="lb-trans"><p>因此，一些新近上市的公司已經開始嘗試利用這些化合物的治療潛力。當這些公司首次上市時，圍繞其項目的興奮迅速推高了它們的交易價值，隨後緊隨其後的拋售使大多數公司陷入了顯著的低谷。</p>
</div><p>Yet there are several strong psychedelic stocks to buy on the dip for potentially lucrative returns. That’s because several studies have shown that LSD, psilocybin and ketamine are all exceptionally effective at treating depression when administered in the correct doses. Thus, it may be just a matter of time before these companies have their moment in the sun.</p>
<div class="lb-trans"><p>然而，有幾隻強勁的致幻股票可以在低谷時購買，以獲取潛在的豐厚回報。這是因為幾項研究表明，當以正確劑量給藥時，LSD、溴酰胺和氯胺酮都非常有效地治療抑鬱症。因此，這些公司可能只是時間問題，它們將迎來他們的輝煌時刻。</p>
</div><h2>Atai Life Sciences (ATAI)</h2>
<div class="lb-trans"><h2>ATAI 生命科學（ATAI）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p>A broader play into alternative therapies, <strong>Atai Life Sciences</strong> (NASDAQ: <strong>ATAI</strong>) is currently researching multiple drugs based on psychedelic substances like ketamine, ibogaine and N,N-dimethyltryptamine (DMT). These compounds, while perhaps known for their recreational use have seen several peer-reviewed studies begin to explore their potential for treating mental health disorders.</p>
<div class="lb-trans"><p>作為對替代療法的更廣泛投資，<strong>ATAI 生命科學</strong>（納斯達克：<strong>ATAI</strong>）目前正在研究基於氯胺酮、伊波甲醚和 N,N-二甲基色胺（DMT）等致幻物質的多種藥物。儘管這些化合物可能以娛樂用途而聞名，但已經有幾項同行評議的研究開始探索它們治療心理健康障礙的潛力。</p>
</div><p>In the case of ATAI, the company has several drugs derived from psilocybin, ketamine and DMT in the pipeline, with itsmost promising one COMP360, entering Phase 3 clinical trials as part of a co-development with another pharmaceutical company. This wide approach to developing treatment does put a financial strain on ATAI’s operations, but it improves the likelihood of a breakthrough and potential Food and Drug Administration (FDA) approval.</p>
<div class="lb-trans"><p>在 ATAI 的情況下，該公司有幾種源自溴酰胺、氯胺酮和 DMT 的藥物正在研發中，其中最有前途的是 COMP360，作為與另一家制藥公司合作的一部分，已進入第三階段臨牀試驗。這種廣泛的治療方法確實給 ATAI 的運營帶來了財務壓力，但提高了突破和潛在的美國食品藥品監督管理局（FDA）批准的可能性。</p>
</div><p>As such, ATAI is one of the best psychedelic stocks to buy on the dip, as it currently trades at a 93% discount on its initial public offering price. Any good news regarding one of its drugs could bolster its value rapidly.</p>
<div class="lb-trans"><p>因此，ATAI 是在低谷時購買的最佳致幻股票之一，因為它目前以其首次公開發行價格的 93% 折扣交易。任何關於其藥物的好消息都可能迅速提振其價值。</p>
</div><h2>Compass Pathways (CMPS)</h2>
<div class="lb-trans"><h2>Compass Pathways（CMPS）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p>I mentioned earlier that ATAI is developing a drug called COMP360 with another company.That company is <strong>Compass Pathways</strong> (NASDAQ: <strong>CMPS</strong>), hence the COMP in the name. This drug is currently the only project in development for CMPS, which means the company represents a very different type of pharmaceutical investment than ATAI.</p>
<div class="lb-trans"><p>我之前提到 ATAI 正在與另一家公司開發一種名為 COMP360 的藥物。那家公司就是 <strong>Compass Pathways</strong>（納斯達克：<strong>CMPS</strong>），因此名稱中有 COMP。這種藥物目前是 CMPS 唯一正在開發的項目，這意味着該公司代表了與 ATAI 非常不同類型的製藥投資。</p>
</div><p>As such, investing in CMPS means committing to the psilocybin side of therapeutics. With this approach, investors know the direct catalyst relies on FDA approval for COMP360. So let’s talk about the studies behind COMP360. Currently, CMPS offers its Phase IIb datasheet on its site for reference on its drug’s efficacy. The Phase IIb trial focused specifically on patients with depression who were resistant to traditional anti-depressant compounds, meaning drugs like selective serotonin reuptake inhibitors were ineffective.</p>
<div class="lb-trans"><p>因此，投資於 CMPS 意味着致力於治療中的溴酰胺一側。通過這種方法，投資者知道直接的催化劑取決於 COMP360 的 FDA 批准。因此，讓我們談談 COMP360 背後的研究。目前，CMPS 在其網站上提供了其第 IIb 階段數據表，以供參考其藥物的功效。第 IIb 階段試驗專注於對傳統抗抑鬱化合物抵抗的患者，這意味着選擇性 5-羥色胺再攝取抑制劑等藥物無效。</p>
</div><p>Of the total participants in the study, 20% reported sustained improvement and therapeutic effects by the 12th week of the study. When you consider that these patients were already exceptionally resistant to treatment, that’s quite impressive. Thus, COMP360 could be worth investing in through psychedelic stocks to buy on the dip such as CMPS.</p>
<div class="lb-trans"><p>在研究的總參與者中，有 20% 報告稱在研究第 12 周時持續改善和治療效果。考慮到這些患者已經對治療非常抵抗，這是相當令人印象深刻的。因此，像 CMPS 這樣的致幻股票可能值得投資。</p>
</div><h2>Cybin (CYBN)</h2>
<div class="lb-trans"><h2>Cybin（CYBN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p>As the name of the company suggests, <strong>Cybin</strong>(NYSEMKT: <strong>CYBN</strong>) specializes in developing three psilocybin-based therapies, CYB003, CYB004, and SPL028, with other psychedelic compounds in preclinical testing. Currently, the stock trades in penny stock territory at just 26 cents a share, which may concern some investors, but it is important to remember that the trading history of the company is fairly new and its products are still vying for FDA approval.</p>
<div class="lb-trans"><p>正如公司名稱所示，<strong>Cybin</strong>（紐交所市場：<strong>CYBN</strong>）專注於開發三種基於溴酰胺的療法，CYB003、CYB004 和 SPL028，同時還在對其他致幻化合物進行臨牀前測試。目前，該股票交易價格僅為 26 美分，處於便士股票領域，這可能會讓一些投資者感到擔憂，但重要的是要記住，該公司的交易歷史相當新，其產品仍在爭取 FDA 批准。</p>
</div><p>Moreover, its psilocybin treatment, specifically the Deuterated Psilocybin Program has been granted breakthrough treatment status by the FDA for treating major depressive disorder following its Phase II trial success. This program has also been tested for treating alcohol abuse disorders and could be a breakthrough therapy for that category as well.</p>
<div class="lb-trans"><p>此外，其溴酰胺治療，特別是重氘化溴酰胺計劃已獲得 FDA 授予治療突破性地位，用於治療重性抑鬱症，其第 II 期試驗取得成功。該計劃還經過測試，用於治療酒精濫用障礙，也可能成為該類別的突破性療法。</p>
</div><p>In the case of Cybin, investors may want to wait until the company can generate revenue, however. Because it is currently in a growth, research and development phase, the company has only reported losses for the last four quarters.</p>
<div class="lb-trans"><p>對於 Cybin，投資者可能希望等到公司能夠產生收入。因為它目前處於增長、研發階段，該公司過去四個季度僅報告了虧損。</p>
</div><p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在發佈日期，Viktor Zarev 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，受到 InvestorPlace.com 發佈指南的約束。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸。</p>
</div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p>
<div class="lb-trans"><p>Viktor Zarev 是一位科學家、研究員和作家，專門通過對準確性和理解的執着來解釋技術股票的複雜世界。</p>
</div>

2024 年夏季值得抄底的 3 只迷幻藥股票